StockMarketWire.com - Clinical stage biotherapeutics firm PureTech Health has reported that its founded entity, Vor Biopharma, has seen the US Food and Drug Administration grant fast track designation to VOR33.

VOR33 is Vor's lead engineered hematopoietic stem cell therapeutic candidate for the treatment of acute myeloid leukemia.


Story provided by StockMarketWire.com